---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-24-000006"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-01-25T23:59:59+00:00"
generated_at: "2026-06-06T17:28:33.946606+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics' Translarna faces withdrawal in Europe after CHMP negative opinion on renewal

## Summary
- CHMP issued negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) after re-examination procedure.
- Negative opinion applies to Translarna for nonsense mutation Duchenne Muscular Dystrophy (nmDMD).
- European Commission to adopt the opinion within 67 days, resulting in withdrawal of Translarna in Europe.
- CEO Matthew B. Klein expressed disappointment, stating decision is against patient community and expert physicians.

## SEC filing metadata
- accession: 0001070081-24-000006
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-01-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000006/0001070081-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000006/tmb-20240125x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-24-000006
- JSON: https://secwatch.observer/filing/0001070081-24-000006.json
- Plain text: https://secwatch.observer/filing/0001070081-24-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.